Hypercalcaemia of malignancy

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Humoral hypercalcaemia from PTH-related peptide is common in squamous and several solid tumours, while breast cancer, myeloma and other bone-involving malignancies can release calcium through osteoclast activation. Some lymphomas increase calcitriol production. The resulting hypercalcaemia impairs renal concentrating ability, promotes natriuresis and vomiting, and creates a dehydration–renal impairment cycle that further reduces calcium excretion.

Symptoms are non-specific: thirst, polyuria, constipation, anorexia, nausea, weakness, cognitive slowing and mood change can be attributed incorrectly to cancer or opioids. More severe disease produces delirium, reduced consciousness, acute kidney injury, shortened QT and arrhythmia. Clinical urgency reflects the concentration, rate of rise, symptoms, renal function and comorbidity rather than a threshold alone.

Acute treatment buys time. Durable control requires identification and treatment of the malignancy, and recurrence is likely if tumour activity persists. Use the live Society for Endocrinology and acute-oncology pathway; antiresorptive choice, renal adjustment, dental risk and repeat dosing belong with experienced oncology, endocrine or renal prescribers.

Key points

Confirm true hypercalcaemia using albumin-adjusted calcium or ionised calcium when albumin, pH, paraprotein or critical illness makes total calcium difficult to interpret.
Malignancy usually raises calcium through PTH-related peptide, focal or diffuse osteolysis, tumour calcitriol production or, less commonly, ectopic PTH; more than one mechanism may coexist.
An intact PTH that is appropriately suppressed supports a non-parathyroid cause, while a non-suppressed result should reopen the possibility of coincident primary hyperparathyroidism.
Restore extracellular volume with 0.9% sodium chloride using repeated cardiorespiratory and urine-output assessment; frailty, heart failure and kidney impairment require slower individualised delivery.
Loop diuretics do not directly treat the high calcium and are reserved for clinically important fluid overload after adequate resuscitation, not routine forced diuresis.
Intravenous bisphosphonate effect is delayed for several days, so record renal function, product, dose and time and do not redose prematurely because the calcium has not fallen the next morning.
Calcitriol-mediated lymphoma may respond to glucocorticoid treatment, while refractory disease may need specialist calcitonin, denosumab, dialysis or tumour-directed intervention.
The episode often signals advanced cancer; combine biochemical treatment with prognosis, symptom control, treatment goals and palliative-care support where appropriate.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Humoral tumour signalling

PTH-related peptide from several solid tumours increases bone resorption and renal calcium retention while native PTH becomes appropriately suppressed.

Osteolytic disease

Skeletal metastases and myeloma activate osteoclasts locally or diffusely, releasing calcium from bone into the circulation.

Tumour calcitriol production

Some lymphomas increase active vitamin D production, enhancing intestinal calcium absorption and creating a mechanism with different treatment implications.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Tumour activity raises calcium
Humoral mediators, osteolysis or calcitriol increase calcium entry from bone or gut and reduce the normal suppressive influence of PTH feedback.
2
Kidney concentration fails
Hypercalcaemia impairs water conservation and promotes sodium loss, causing polyuria and extracellular volume depletion that further reduces renal calcium clearance.
3
Renal clearance falls
Dehydration and acute kidney injury reduce calcium excretion, forming a cycle that intensifies the biochemical abnormality.
4
Organ toxicity emerges
Rising calcium alters cerebral, gastrointestinal, neuromuscular and cardiac function, with severity shaped by concentration, rate of rise and comorbidity.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Volume depletionRed flag

Thirst, polyuria, dry mucosa, tachycardia, postural hypotension and reduced urine output reflect nephrogenic water loss and worsening renal calcium clearance.

Neuropsychiatric changeRed flag

Fatigue, poor concentration, depression, confusion, delirium, seizure or coma can represent calcium toxicity and should not be assigned automatically to malignancy progression.

Gastrointestinal burden

Anorexia, nausea, vomiting, constipation and abdominal discomfort intensify dehydration and may be compounded by opioid, antiemetic or treatment effects.

Cardiorenal toxicityRed flag

Shortened QT, bradyarrhythmia or other conduction disturbance with acute kidney injury or oliguria marks high-risk disease requiring monitored correction.

Cancer mechanism clues

Bone pain, pathological fracture, known skeletal metastases, myeloma features or lymphoma symptoms guide investigation but cannot reliably determine the biochemical mechanism alone.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Repeat adjusted or ionised calciumFirst step
Why
Confirm the abnormality, grade its trajectory and avoid albumin or paraprotein artefact.
Interpretation and limitations
Use ionised calcium when total values are unreliable; compare with previous results because a rapid rise can cause severe symptoms at a lower absolute concentration.
02
Urea, creatinine, sodium, potassium, magnesium and phosphate
Why
Quantify dehydration, renal injury and electrolyte constraints before fluid and antiresorptive treatment.
Interpretation and limitations
Renal dysfunction increases treatment risk and may reflect the calcium itself, obstruction, sepsis or myeloma; low phosphate can support PTH-related peptide activity but is not diagnostic.
03
Intact parathyroid hormone
Why
Separate PTH-independent malignant hypercalcaemia from coincident parathyroid-driven disease.
Interpretation and limitations
A suppressed result fits malignancy or another PTH-independent cause; an inappropriately normal or raised value warrants endocrine reassessment even in a patient with known cancer.
04
Mechanism-directed blood tests
Why
Identify PTH-related peptide, calcitriol excess, myeloma or another treatable cause when results change care.
Interpretation and limitations
Select PTHrP, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, serum free light chains and electrophoresis with specialist guidance rather than ordering an indiscriminate panel.
05
ECG and continuous monitoring when severe
Why
Detect conduction disturbance and provide a safe environment for rapid electrolyte and volume change.
Interpretation and limitations
A shortened QT may support calcium effect, but ECG sensitivity is limited; arrhythmia, digoxin exposure or major companion electrolyte abnormality increases urgency.
06
Cancer staging and complication imaging
Why
Find the tumour burden, osteolysis, obstruction, fracture or spinal cord threat driving morbidity.
Interpretation and limitations
Choose imaging from symptoms and known disease, coordinating it with acute oncology; biochemical correction must not delay urgent management of cord compression or fracture.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Primary hyperparathyroidism

A non-suppressed PTH suggests coincident parathyroid disease rather than automatically attributing hypercalcaemia to a known cancer.

Medicine or supplement effect

Thiazides, lithium, calcium and vitamin products may contribute; a complete exposure review can reveal a reversible additional driver.

Granulomatous disease

Non-malignant macrophage calcitriol production can resemble lymphoma physiology, with inflammatory history and targeted assessment helping distinguish the cause.

Immobilisation hypercalcaemia

Prolonged immobility increases bone resorption, particularly in high-turnover states, and may coexist with cancer without being tumour-mediated.

Additional chapter-specific clues

Alternative parathyroid disease

PTH should be suppressed by genuine hypercalcaemia; a non-suppressed value suggests coincident primary or tertiary hyperparathyroidism rather than proving malignant causation.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01StabiliseConfirm severity and restore circulationFirst stepA patient with suspected or known malignancy has symptomatic, rapidly rising or severe hypercalcaemia.

1Use ABCDE, ECG and neurological assessment, repeat calcium with renal and companion electrolytes, establish accurate fluid balance and stop avoidable calcium-raising medicines or supplements.
2Begin 0.9% sodium chloride according to the Society and local acute-oncology schedule, reassessing lungs, pressure, perfusion and urine output after each stage.
3EscalationEscalate shock, oliguria, severe neurological change, arrhythmia or inability to rehydrate safely to critical care, renal and endocrine teams while treating the precipitating illness.

02SuppressReduce pathological bone calcium releaseTrue malignant hypercalcaemia persists after initial volume assessment and antiresorptive treatment is appropriate.

1Review renal function, prior antiresorptive exposure, calcium and vitamin D status, dental considerations and goals of care with an experienced oncology or endocrine prescriber.
2Administer the chosen intravenous bisphosphonate using its licensed dilution and infusion time, documenting when a nadir is expected so early lack of response is not mistaken for failure.
3For severe refractory disease or a mechanism unsuitable for standard bisphosphonate, obtain specialist advice on calcitonin, denosumab, glucocorticoid treatment or renal replacement therapy.

03ExplainDefine the mechanism and malignancyHypercalcaemia is newly associated with possible cancer, unexpectedly recurrent or biochemically atypical.

1Interpret paired PTH first, then use history, examination, blood count, renal profile, myeloma testing and mechanism-specific vitamin D or PTHrP studies where they will change management.
2Investigate symptoms for skeletal lesions, fracture, obstruction, infection and acute vascular disease, arranging cancer imaging through the appropriate rapid or acute pathway.
3Do not let known malignancy suppress a second diagnosis: primary hyperparathyroidism, medicines, granulomatous disease and thyrotoxicosis can coexist.

04PlanPrevent recurrence and align goalsCalcium and hydration improve after acute treatment.

1Monitor through the expected antiresorptive nadir for hypocalcaemia, renal injury and phosphate or magnesium decline, then define the next calcium review and who owns it.
2Coordinate tumour-directed treatment, bone protection, hydration access, medicine reconciliation and advice for thirst, vomiting, constipation or cognitive change.
3Discuss prognosis and treatment burden honestly, integrating specialist palliative care when symptom-focused management better reflects the patient’s priorities.

Key medicines and prescribing safety3 treatments · regimens, roles and cautions

Reverses the volume-depletion cycle, restores renal perfusion and increases urinary calcium clearance before delayed antiresorptive benefit develops.

Intravenous 0.9% sodium chloride

Use the staged volume and rate in the current Society for Endocrinology and local acute-oncology pathway, adjusting each prescription to deficit, urine output, age, heart failure and renal function rather than applying a universal daily volume.

Repeatedly examine for pulmonary oedema and worsening heart or kidney failure. Do not use routine loop diuresis to force calcium excretion; reserve diuretic treatment for genuine overload after adequate intravascular replacement.

Inhibits osteoclast-mediated calcium release and provides delayed control after the immediate volume deficit is being corrected.

Zoledronic acid for tumour-induced hypercalcaemia

The current SmPC recommends a single 4 mg intravenous dose for adults with albumin-corrected calcium at least 3.0 mmol/L, infused over no less than 15 minutes by an experienced prescriber after hydration and renal assessment.

Check creatinine, hydration, calcium, phosphate and magnesium and follow the exact renal and product instructions. Avoid premature repeat dosing; consider hypocalcaemia, acute-phase reaction, renal injury and osteonecrosis risk in the broader oncology plan.

Reduces pathological calcitriol production in selected haematological malignancies rather than serving as routine treatment for every raised calcium.

Mechanism-specific glucocorticoid treatment

For confirmed or strongly suspected calcitriol-mediated lymphoma or another steroid-responsive mechanism, select agent and dose with oncology or endocrine specialists from the disease-specific live protocol; no single regimen covers all malignant causes.

Establish the likely mechanism and screen infection risk before treatment where urgency permits. Monitor glucose, mental state, fluid retention and interacting cancer therapy, and do not delay more appropriate tumour-directed or antiresorptive treatment.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Renal failure

Persistent nephrogenic water loss, vomiting and calcium-related kidney injury can produce oliguria and limit standard fluid or antiresorptive treatment.

Delirium and coma

Cerebral calcium toxicity causes cognitive slowing, mood change and weakness before progressing to delirium, seizure or reduced consciousness.

Cardiac rhythm disturbance

Shortened repolarisation, dehydration and interacting electrolyte or medicine effects can cause bradyarrhythmia or other clinically significant conduction disturbance.

Recurrence

Acute calcium control is temporary when tumour activity persists, so recurrent episodes often indicate ongoing cancer burden and require goals-of-care review.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Repeat calcium, renal function and companion electrolytes at a frequency determined by severity during fluids, then through the expected two-to-four-day antiresorptive response.
Maintain accurate oral and intravenous input and urine output, daily weight and repeated chest examination so fluid prescription follows physiology rather than a preset total.
Use cardiac monitoring for severe calcium elevation, arrhythmia, digoxin exposure or important potassium and magnesium disturbance, with repeat ECG after meaningful change.
Watch for post-treatment hypocalcaemia, especially with vitamin D deficiency, extensive osteolytic disease, renal impairment or potent antiresorptive therapy.
Record cognitive, nausea, bowel, thirst and pain response because symptom improvement may lag behind the first biochemical change and requires supportive treatment.
Arrange an explicit post-discharge calcium date and acute-oncology ownership; recurrence can occur rapidly when the malignancy remains active.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

PTH must be interpreted physiologically

A laboratory-normal PTH is abnormal when calcium is high because healthy glands should suppress; this clue can reveal coincident primary hyperparathyroidism.

Fluid response precedes drug response

Calcium may improve with restored filtration before bisphosphonate action, while the antiresorptive nadir commonly takes several days to appear.

Paraprotein can distort totals

Myeloma and major protein abnormalities can make total or adjusted calcium misleading; ionised calcium resolves clinically discordant results.

Mechanism changes second-line care

Humoral, osteolytic and calcitriol-mediated disease do not respond identically, making targeted investigation valuable when initial treatment fails.

Diuretics are not calcium antidotes

Loop diuretics can worsen the initiating volume deficit and electrolyte losses; they have a role only when resuscitation causes clinically important overload.

Goals belong in the prescription

For advanced cancer, a burdensome intervention with short-lived biochemical benefit may not match the person’s priorities; treatment planning should make that trade-off visible.

11Common pitfallsFrequent interpretation and management errors.

01
Treating a mildly high total calcium as definite toxicity without checking albumin, ionised calcium or a repeat sample when the clinical picture conflicts.
02
Giving a rapid large fluid schedule to a frail person with heart or renal failure without serial respiratory examination and urine-output reassessment.
03
Using furosemide routinely before correcting volume depletion and thereby worsening renal perfusion, potassium loss and hypercalcaemia.
04
Repeating zoledronic acid the next day because calcium remains raised, despite its delayed nadir and the accumulating risk of renal and mineral toxicity.
05
Assuming known cancer proves the mechanism when PTH is non-suppressed or another medicine and endocrine cause fits better.
06
Normalising the calcium but failing to communicate recurrence risk, definitive oncology decisions and a proportionate palliative plan.